Alexithymia, anxiety, and depression in patientswith vitiligo

Aim: Characterized by hypopigmented cutaneous lesions, vitiligo is a chronic dermatological disease with psychosocial effects. Thegoal of our study is to search alexithymia, anxiety, and depression levels in vitiligo patients. Materials and Methods: In total, 50 vitiligo patients aged over 18 years and 70 healthy control subjects compatible with age andgender were evaluated. All participants filled in the questionnaires of the Toronto Alexithymia Scale (TAS-20), Beck Anxiety inventory(BAI), and Beck Depression inventory (BDI). Results: In vitiligo patients, depression and anxiety levels were meaningful higher than the controls (p = 0.009, p = 0.000, respectively),but there was no meaningful difference between alexithymia scores (p = 0.103). There was no correlation between psychiatric scalescores and disease duration, age, gender, and education levels in vitiligo patients. A positive correlation was determined betweenalexithymia levels and anxiety and depression levels in vitiligo. Conclusion: In this study, anxiety and depression levels were found to be high in patients with vitiligo. According to the results of ourstudy, vitiligo should not only be evaluated dermatologically but also psychologically. In this way, we think that patients' compliancewith treatment and treatment success will increase.

PDF

___

1. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012;25: 1-13.
2. Cupertino F, Niemeyer-Corbellini JP, Ramos-E-Silva M. Psychosomatic aspects of vitiligo. Clinics in Dermatology 2017;35:292-7.
3. Sarac G, N Altunisik, Sener S, et al. Evaluation of changes in neutrophil-lymphocyte ratio and plateletlymphocyte ratio in patients with vitiligo. Ann Med Res 2019; 26:1344-6.
4. Salman A, Kurt E, Topcuoglu V, et al. Social anxiety and quality of life in vitiligo and acne patients with facial involvement: a cross-sectional controlled study. Am J Clin Dermatol 2016;27:305-11.
5. Acar ST, Ayyildiz E, Camkurt A, et al. Vitiligo ve Aleksitimi. Literatür Sempozyum 2016;9:5-10.
6. Van Moffaert M. Psychodermatology: an overview. Psychoder Psychosom 1992;58:125-36.
7. Jafferany M. Psychodermatology: a guide to understanding common psychocutaneous disorders. Prim Care Companion J Clin Psychiatry 2007;9:203- 13.
8. Sifneos PE. Alexithymi and its relationship to hemispheric specialization, affect, and creativity. Psychiatr Clin North Am 1988;11:287-92.
9. Namdar ND, Arıkan I. The relationship between alexithymia, anxiety, depression, and severity of the disease in psoriasis patients. J Surg Med 2020;4:226- 9.
10. Taycan O, Ozdemir A, Erdogan S. Alexithymia and Somatization in Depressed Patients: The Role of the Type of Somatic Symptom Attribution. Arch Neuropsychiatry 2017;54:99-104.
11. Picardi A, Pasquini P, Cattaruzza MS, et al. Stressful life events, social support, attachment security and alexithymiain vitiligo. A case–control study. Psychother Psychosom 2003;72:150-8.
12. Bagby RM, Parker JDA, Taylor GJ. The twenty item Toronto Alexithymia Scale I-II. Item selection and cross validation of the factor structure and Convergent, Discriminant, and Concurrent Validity. J Psychosom Res 1994;38:23-40.
13. Güleç H, Yenel A. 20 Maddelik Toronto Aleksitimi Ölçeği Türkçe Uyarlamasının Kesme Noktalarına Göre Psikometrik Özellikleri. Klin. Psikiyatr Derg 2010;13:108-12.
14. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin. Psychol 1988;56:893-7.
15. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: Psychometric properties. J Cognitive Psychother 1998;12:163-72.
16. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-71.
17. Hisli N. Beck Depresyon Ölçeği’nin bir Türk örnekleminde geçerlilik ve güvenilirliği. Psikoloji Dergisi 1988;6:118-22.
18. Noh S, Kim M, Park CO, et al. Comparison of the psychological impacts of asymptomatic and symptomatic cutaneous diseases: vitiligo and atopic dermatitis. Ann Dermatol 2013;25:454-61.
19. Arican O, Koc K, Ersoy L. Clinical characteristics in 113 Turkish vitiligo patients. Acta Dermatovenereol APA 2008;17:129-32.
20. Mechri A, Amri M, Douarika AA, et al. Psychiatric morbidity and quality of life in vitiligo: A case controlled study. Tunis Med 2006;84:632-35.
21. Aksoy M, Selcuk LB. Quality of Life, Anxiety, Depression and Obsessive Compulsive Disorder Levels in Patients with Vitiligo. Van Tıp Derg 2019;26:273-8.
22. Prcic S, Durovic D, Duran V, et al. Some psychological characteristics of children and adolescents with Vitiligo--Our results. Medicinski Pregled 2006;59:265- 9.
23. Bilgic O, Bilgic A, Akis HK, et al. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin Exp Dermatol 2011;36:360-5.
24. Willemsen R, Roseeuw D, Vanderlinden J. Alexithymia and dermatology: the state of the art. Int J Dermatol 2008;47:903-10.
25. Dehghani F, Dehghani F, Kafaie P, et al. Alexithymia in different dermatologic patients. Asian J Psychiatr 2017;25:42-5.
26. Kocabaş E. Alopesi Areata ve Vitiligoda Aleksitimi, Celal Bayar Üniversitesi Tıp Fakültesi, Dermatoloji Anabilimdalı, Uzmanlık Tezi Manisa 2011.
27. Balaban OD, Atagun MI, Ozguven HD, et al. Psychiatric morbidity in patients with vitiligo. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi 2011;24:306- 13.
28. Lane RD, Sechrest L, Riedel R. Sociodemographic correlates of alexithymia. Compr Psychiatry 1998;39:377-85.
29. Mason O, Tyson M, Jones C, et al. Alexithymia: its prevalence and correlates in a British undergraduate sample. Psychol Psychother 2005;78:113-25.